Navigation Links
Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
Date:4/9/2012

SILVER SPRING, Md., April 9, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTC Bulletin Board: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS has signed a Letter of Intent with PharmaLife® for placement of Clotamin® with leading pharmacies in the Russian Federation.   

The Letter of Intent outlines the terms and conditions of a proposed transaction that could see Clotamin distributed by several pharmacy and retail chains in the Russian Federation, including product placement with leading wholesalers Imperia-Pharma, the Dr. Stoletov pharmacy chain (414 locations), and other small retail pharmacies associated with Imperia-Pharma.  PharmaLife is also expected to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product launch.

"Potential demand for Clotamin is worldwide and this Letter of Intent to export into the Russian marketplace is the first agreement intended to meet that international demand," stated Mackie A. Barch, CEO of Sunpeaks.  "We look forward to working closely with PharmaLife and our new possible distributors to build market awareness and sales of Clotamin across Russia.  If successful, the Company intends to utilize this expansion strategy to penetrate other international markets that share similar potential."

PharmaLife is a premier integrated total healthcare solution provider, combining the nation's leading healthcare services company with a retail pharmacy chain.  With over 10 years of dynamic growth and experience, PharmaLife delivers pharmaceutical services to thousands of clients and also provides business development and consulting services to assist other healthcare professionals reach their goals.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market.   HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements.  These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.  The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission.  All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement.  Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Sunpeaks Ventures, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington
2. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
3. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
4. Sunpeaks Ventures Announces Clotamin to Be Sold at Winn-Dixie Locations in South Florida
5. Sunpeaks Ventures Announces Clotamin to be Sold at Bravo Supermarkets in South Florida
6. Sunpeaks Ventures to Participate in ECRM Conference and Expo
7. Sunpeaks Ventures Announces Clotamin to be Sold at Navarro Discount Pharmacies
8. Sunpeaks Ventures Announces Clotamin available on Walgreens.com
9. Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector
10. Sunpeaks Ventures Completes Acquisition of Healthcare Distribution Specialists LLC
11. GMH Ventures Acquires Majority Ownership in Dynamic Healthcare Services, Leading Provider of Medical Equipment and Respiratory Therapy Products and Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):